Corticosteroid-triggered acute skeletal muscle loss in lipodystrophy: A case report.
Takayoshi SasakoKen SuzukiSara OdawaraHirotsugu SuwanaiNaoko AkutaNaoto KubotaKohjiro UekiTakashi KadowakiToshimasa YamauchiPublished in: Journal of diabetes investigation (2024)
The potential liability to hypercatabolism in lipodystrophy remains to be fully elucidated. Here we report a 28-year-old Japanese woman with acquired generalized lipodystrophy, who presented with recurrence of panniculitis and anemia. After corticosteroid treatment was started, she showed rapid reductions in body weight and lean mass by 15% at maximum, accompanied by an elevated urea nitrogen/creatinine ratio, which recovered almost fully as the corticosteroid treatment was tapered and discontinued. She had multiple risk factors for hypercatabolism: lack of metabolic reserves, insulin resistance, and hyperglycemia due to lipodystrophy, lowered daily activity due to anemia, persistent inflammation, and wasting associated with panniculitis, and relatively insufficient energy and protein intake during hospitalization. More attention should be paid to the potential liability to hypercatabolism in patients with lipodystrophy, and to skeletal muscle loss as an adverse effect of corticosteroid treatment in patients at high risk, such as those with diabetes or decreased metabolic reserves.
Keyphrases
- skeletal muscle
- insulin resistance
- body weight
- chronic kidney disease
- type diabetes
- cardiovascular disease
- liver failure
- oxidative stress
- adipose tissue
- physical activity
- intensive care unit
- working memory
- emergency department
- polycystic ovary syndrome
- replacement therapy
- hepatitis b virus
- case report
- body mass index
- combination therapy
- human health
- body composition
- weight gain
- electronic health record